Clinical Trial Update: Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules [Phase 4]

View source ↗

Summary

Phase 4 study update evaluating weekly vs biweekly dosing of subcutaneous immunoglobulin IgPro20 (Hizentra) in patients with primary or secondary immune deficie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Deficiency

Drugs mentioned

• IgPro20 (Hizentra) (immune globulin, human, subcutaneous)

Snippet

Sponsor: CSL Behring | Conditions: Primary Immune Deficiency, Secondary Immune Deficiency | Phase 4 | Status: COMPLETED